Simplex Trading
ECYT

Simplex Trading’s Endocyte, Inc. Common Stock ECYT Stock Holding History

Simplex Trading’s Portfolio ECYT Stock Details ECYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-16,492
Closed -$283K – 8510
2018
Q2 		$227K Buy
+16,492
New +$196K ﹤0.01% 3335
2017
Q4 		– Sell
-4,128
Closed -$19.7K – 7165
2017
Q3 		$5K Buy
4,128
+809
+24% +$1.13K ﹤0.01% 4480
2017
Q2 		$4K Sell
3,319
-5,713
-63% -$12.3K ﹤0.01% 4870
2017
Q1 		$23K Buy
9,032
+8,549
+1,770% +$19.8K ﹤0.01% 3126
2016
Q4 		$1K Buy
+483
New +$1.39K ﹤0.01% 5661
2016
Q3 		– Sell
-2,241
Closed -$6.98K – 6864
2016
Q2 		$7K Sell
2,241
-26,581
-92% -$97.4K ﹤0.01% 3994
2016
Q1 		$89K Buy
28,822
+4,746
+20% +$15.5K 0.01% 1460
2015
Q4 		$96K Buy
24,076
+13,739
+133% +$63.3K 0.01% 1395
2015
Q3 		$47K Buy
10,337
+9,999
+2,958% +$52.3K ﹤0.01% 2057
2015
Q2 		$1K Sell
338
-10,291
-97% -$61.7K ﹤0.01% 4932
2015
Q1 		$66K Buy
10,629
+4,684
+79% +$27K 0.01% 1365
2014
Q4 		$37K Buy
+5,945
New +$36.2K ﹤0.01% 1591

Other funds holding ECYT

OTC
Opera Trading Capital Paris, France $419M AUM 0.58% 1-Year Est. Return
CA
Claro Advisors Boston, Massachusetts $830M AUM 21.8% 1-Year Est. Return

Simplex Trading's ECYT Position: Q3 2018 in Review

Simplex Trading sold out of Endocyte, Inc. Common Stock (ECYT) in Q3 2018, closing a stake of 16,492 shares — an estimated $283K sold.

Simplex Trading first reported a position in ECYT in Q4 2014 and held it in 12 quarters. The position peaked at $227K in Q2 2018. 139 funds tracked by Wall St. Rank hold ECYT as of Q3 2018.

  • Simplex Trading reported no remaining Endocyte, Inc. Common Stock position as of Q3 2018 after selling out during the quarter.
  • Simplex Trading sold 16,492 Endocyte, Inc. Common Stock shares in Q3 2018, an estimated $283K.
  • Simplex Trading first reported a position in Endocyte, Inc. Common Stock in Q4 2014 and held it in 12 quarters.
  • Simplex Trading's Endocyte, Inc. Common Stock position peaked at $227K in Q2 2018.
  • 139 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q3 2018.

Based on Simplex Trading's 13F filing for Q3 2018, filed 23 Oct 2018.